Durable gene therapy with a robust AAV-LNP delivery system allowing for reduced AAV dose - Poseida

Skip to content

Technology
Pipeline
About Us
Investors & Media
Careers & Culture
Clinical Trials
News Center
Contact Us

Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

American Society of Gene and Cell Therapy (ASGCT) Meeting 2024

<img width="201" height="38" src="https://poseida.com/wp-content/uploads/2023/03/poseida-logo-white.png" class="image wp-image-92 attachment-full size-full" alt="“Poseida” Therapeutics - Bold solutions with the Capacity to Cure" style="max-width: 100%; height: auto;" decoding="async" />

Contact
Privacy Policy
Expanded Access Policy
Accessibility Statement

© 2024 Poseida Therapeutics, Inc. | All rights reserved.

<img width="201" height="38" src="https://poseida.com/wp-content/uploads/2023/03/poseida-logo-white.png" class="image wp-image-92 attachment-full size-full" alt="“Poseida” Therapeutics - Bold solutions with the Capacity to Cure" style="max-width: 100%; height: auto;" decoding="async" />

© 2024 Poseida Therapeutics, Inc.
All rights reserved.

Contact
Privacy Policy
Expanded Access Policy
Accessibility Statement